Ileadbms Co. Ltd. has described son of sevenless homolog 1 (SOS1)/GTPase KRAS G12D mutant interaction and SOS1/GTPase KRAS G12C mutant interaction inhibitors reported to be useful for the treatment of cancer, arteriovenous malformations, cardiofaciocutaneous syndrome, Costello syndrome and more.